This company has been marked as potentially delisted and may not be actively trading. NASDAQ:AXNX Axonics (AXNX) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipShort InterestSustainabilityTrendsBuy This Stock About Axonics Stock (NASDAQ:AXNX) 30 days 90 days 365 days Advanced Chart Remove Ads Get Axonics alerts:Sign Up Key Stats Today's Range$70.98▼$70.9850-Day Range$69.66▼$70.9852-Week Range$66.32▼$71.05VolumeN/AAverage Volume432,118 shsMarket Capitalization$3.63 billionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingHold Company OverviewAxonics, Inc., a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of OAB, UR, and FI. The company also offers Bulkamid, a urethral bulking agent to treat female stress urinary incontinence. It sells its products through a direct sales force and distributors in the United States, the United Kingdom, Germany, the Netherlands, Nordic countries, and internationally. The company was formerly known as Axonics Modulation Technologies, Inc. and changed its name to Axonics, Inc. in March 2021. Axonics, Inc. was incorporated in 2012 and is based in Irvine, California.Read More… Remove Ads Receive AXNX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Axonics and its competitors with MarketBeat's FREE daily newsletter. Email Address AXNX Stock News HeadlinesPositive Long-Term Outlook for Boston Scientific Post-Axonics Acquisition: Buy Rating AffirmedJanuary 8, 2025 | markets.businessinsider.comAxonics Modulation Technologies Merges and Delists from NasdaqNovember 16, 2024 | markets.businessinsider.comCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69% dividend from Tesla… Which could put up to $7,013 in your pocket every month…April 8, 2025 | Investors Alley (Ad)Boston Scientific Closes Acquisition of Axonics, Inc.November 15, 2024 | prnewswire.comPiper Sandler Keeps Their Hold Rating on Axonics Modulation Technologies (AXNX)September 20, 2024 | markets.businessinsider.comAxonics defeats Medtronic lawsuit in spine-stimulation patent trialSeptember 19, 2024 | reuters.comJury Finds Axonics Did Not Infringe Any of Three Patents-in-SuitSeptember 18, 2024 | marketwatch.comAxonics Prevails in Patent Infringement Lawsuit with MedtronicSeptember 18, 2024 | businesswire.comSee More Headlines AXNX Stock Analysis - Frequently Asked Questions How were Axonics' earnings last quarter? Axonics, Inc. (NASDAQ:AXNX) released its earnings results on Thursday, November, 7th. The company reported $0.16 earnings per share for the quarter, topping analysts' consensus estimates of $0.11 by $0.05. Axonics's quarterly revenue was up 24.8% compared to the same quarter last year. When did Axonics IPO? Axonics (AXNX) raised $100 million in an initial public offering (IPO) on Wednesday, October 31st 2018. The company issued 6,700,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch and Morgan Stanley served as the underwriters for the IPO and Wells Fargo Securities and SunTrust Robinson Humphrey were co-managers. What other stocks do shareholders of Axonics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Axonics investors own include Humana (HUM), American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), NVIDIA (NVDA), TotalEnergies (TTE) and The RMR Group (RMR). Company Calendar Last Earnings11/07/2024Today4/08/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryMedical Equipment Current SymbolNASDAQ:AXNX CIK1603756 Webwww.axonics.com Phone(949) 396-6322Fax949-396-6321Employees610Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.12) Trailing P/E RatioN/A Forward P/E Ratio322.64 P/E GrowthN/ANet Income$-6,090,000.00 Net Margins-1.31% Pretax Margin-0.70% Return on Equity0.36% Return on Assets0.31% Debt Debt-to-Equity RatioN/A Current Ratio8.16 Quick Ratio6.40 Sales & Book Value Annual Sales$366.38 million Price / Sales9.90 Cash Flow$0.13 per share Price / Cash Flow561.96 Book Value$12.59 per share Price / Book5.64Miscellaneous Outstanding Shares51,110,000Free Float50,163,000Market Cap$3.63 billion OptionableOptionable Beta0.82 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (NASDAQ:AXNX) was last updated on 4/8/2025 by MarketBeat.com Staff From Our PartnersElon’s 2025 Silver Crisis (What It Means for You)Silver isn't just a safe haven for your wealth—it's a critical resource in the global tech and energy race. Wi...GoldenCrest Metals | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsMusk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to h...InvestorPlace | Sponsored**Breaking NEWS* This Company Starts To Rally As it Reduces $20 Million in Debt**Breaking NEWS* This Company Starts To Rally As it Reduces $20 Million in Debt Discover why Notable Names ...Huge Alerts | SponsoredTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredAmazon ShockerJeff Bezos quietly backing world-changing tech (not AI) The Amazon founder is quietly advancing a radical t...Stansberry Research | SponsoredDividend cuts are destroying retirements… is yours next?The market is on edge. Every day, another company slashes its dividend, leaving investors scrambling. Intel...Investors Alley | SponsoredFBI Warns: Wave Of Retiree Cyber Hacks Coming In 2025Try to think back to the fall of 2008… The pandemic accelerated America's descent into a “no-cash society” ...Colonial Metals | SponsoredTrump’s Secret WeaponHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Axonics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Axonics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.